Pfizer Inc (PFE)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $164.67B
Last updated: Nov 17, 2026 at 4:43 PM ET
Pfizer Inc (PFE) Stock Chart
Pfizer (PFE) has a latest price of $28.46 on Nov 17, 2026, 8.2% below its 52-week high of $30.99. Its price rose 15.5% over the past 12 months. The month-end price fell 3.8% over the 10 years through Oct 2026, a compound annual decline of 0.4%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $59.05 in Dec 2021 and its lowest $23.29 in Jul 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart PFE with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for PFE.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 2.3%, and over 6 months it rose 12.9%. The month-end price fell 0.1% over the 3 years through Oct 2026.
| Period | Change |
|---|---|
| 1 month | -1.9% |
| 3 months | +2.3% |
| 6 months | +12.9% |
| 12 months | +15.5% |
| 12 months, with dividends | +22.4% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -0.1% | 0.0% |
| 5 years | -30.2% | -6.9% |
| 10 years | -3.8% | -0.4% |
Price by Year
Its best calendar year was 2021, when the price rose 60.4%, and its weakest was 2023, when it fell 43.8%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $30.52 | +22.6% |
| 2025 | $24.90 | -6.1% |
| 2024 | $26.53 | -7.8% |
| 2023 | $28.79 | -43.8% |
| 2022 | $51.24 | -13.2% |
| 2021 | $59.05 | +60.4% |
| 2020 | $36.81 | -6.0% |
| 2019 | $39.18 | -10.2% |
| 2018 | $43.65 | +20.5% |
| 2017 | $36.22 | +11.5% |
Trading Range
The price is 0.1% below its 50-day average of $28.47 and 7.6% above its 200-day average of $26.45.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $28.46 | |
| 52-week high | $30.99 | -8.2% |
| 52-week low | $22.76 | +25.0% |
| 50-day average | $28.47 | -0.1% |
| 200-day average | $26.45 | +7.6% |
Price Risk
Over 3 years, its largest fall from a peak was 29.0%.
| Measure | Value |
|---|---|
| 1-year beta | 0.29 |
| Largest fall, 1 year | -16.9% |
| Largest fall, 3 years | -29.0% |
Valuation
Pfizer traded at 7.7x earnings at the end of 2025, against a 5-year median of 8.5x and a 10-year median of 12.6x.
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About PFE
What is PFE's 1-year price change?
Pfizer's price rose 15.5% over the past 12 months. With dividends included, the 12-month total return was 22.4%.
What is PFE's 5-year price change?
Pfizer's month-end price fell 30.2% over the 5 years through Oct 2026, a compound annual decline of 6.9%. These figures leave out dividends.
What is PFE's 52-week high and low?
Pfizer's 52-week high is $30.99 and its 52-week low is $22.76. Its latest price of $28.46 on Nov 17, 2026 is 8.2% below the high.
What is PFE's beta?
Pfizer's 1-year beta against the S&P 500 is 0.29, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 16.9%.
Is the PFE chart free?
Yes. Advanced Charting for PFE is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
PFE pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts